Haneen Shalabi, D.O.
Dr. Shalabi's primary research interests are novel immunotherapy targets for chemo-resistant acute lymphoblastic leukemia. Her clinical focus is the treatment of relapsed/refractory pediatric patients with hematologic malignancies utilizing chimeric antigen receptor (CAR) T cell therapies. Additional areas of interest include neurocognitive effects of immunotherapy in pediatric patients and bone marrow transplantation for patients with malignant and non-malignant diseases.
1) pediatric leukemia, 2) chimeric antigen receptor (CAR) T cell therapy for pediatric leukemia, 3) immunotherapy for relapsed/refractory hematologic malignancies,
4) cognitive effects post immunotherapy
Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell TherapyOpen - Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-00-0-067Investigator Haneen Shalabi, D.O.Share this trial: Referral Contacts
Contact Name Phone Number NCI Pediatric Leukemia Lymphoma BMT Team (240)760-6970
Dr. Shalabi focuses on translation of chimeric antigen receptor therapy to treat high-risk hematologic malignancies in pediatric patients. She works in conjunction with the neurobehavioral team to assess patients receiving immunotherapy for neurocognitive changes.
Selected Key Publications
Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.Journal of Immunotherapy. 41: 350-358, 2018. [ Journal Article ]
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.Hematologica. 103: e215-e218, 2018. [ Journal Article ]
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.Frontiers in Pediatrics. 3: 1-12, 2015. [ Journal Article ]
Cell-based Therapies: A New Frontier of Personalized Medicine.In: Novel Designs of Early Phase Trials for Cancer Therapeutics. Elsevier Science 2018. [ Book Chapter ]
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nature Medicine. 24: 20-28, 2018. [ Journal Article ]
Dr. Shalabi received her medical degree in 2010 from Midwestern University, Chicago College of Osteopathic Medicine. In 2013, she completed her pediatric residency in Chicago at Loyola University Medical Center, and then completed her fellowship in pediatric hematology/oncology at Children's National Medical Center in Washington DC in 2016. From 2016-2018, she joined the Pediatric Oncology Branch as an advanced studies fellow with a focus in pediatric cellular therapies.